ATR and cancer: While the synthetic lethality data for Polθ suggest specific settings in which Polθ inhibitors could be beneficial (HR‐deficient tumors, TP53BP1 mutants or DNA‐PKcs‐mutant cancers) and based on the role of Polθ in replication associated lesions, they could also be used in combination therapy with RS inducing agents, such as ATR and topoisomerase inhibitors.164